Sarepta Therapeutics (NASDAQ:SRPT) Raised to “Buy” at Wall Street Zen

Sarepta Therapeutics (NASDAQ:SRPT) was upgraded by Wall Street Zen from a “hold” rating to a “buy” rating in a research note issued on Saturday.

Several other equities research analysts have also weighed in on the stock. Mizuho increased their target price on shares of Sarepta Therapeutics from $26.00 to $31.00 and gave the stock an “outperform” rating in a report on Thursday, March 12th. Deutsche Bank Aktiengesellschaft boosted their price target on shares of Sarepta Therapeutics from $12.00 to $14.00 and gave the company a “sell” rating in a report on Thursday, March 26th. HC Wainwright restated a “sell” rating on shares of Sarepta Therapeutics in a research report on Thursday, April 16th. Wedbush raised their price objective on Sarepta Therapeutics from $29.00 to $35.00 and gave the stock an “outperform” rating in a research note on Thursday, March 26th. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $37.00 price objective on shares of Sarepta Therapeutics in a research note on Thursday, March 19th. Eight investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and six have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $24.81.

Sarepta Therapeutics Stock Performance

Shares of SRPT stock opened at $19.28 on Friday. The stock has a market cap of $2.04 billion, a PE ratio of -20.08, a price-to-earnings-growth ratio of 0.20 and a beta of 0.21. The stock has a 50-day moving average of $17.85 and a 200-day moving average of $19.34. The company has a debt-to-equity ratio of 0.56, a current ratio of 4.63 and a quick ratio of 2.62. Sarepta Therapeutics has a one year low of $10.41 and a one year high of $25.32.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $3.16 earnings per share for the quarter, topping the consensus estimate of $0.98 by $2.18. The business had revenue of $730.80 million for the quarter, compared to analyst estimates of $474.15 million. Sarepta Therapeutics had a negative net margin of 2.94% and a positive return on equity of 7.56%. Sarepta Therapeutics’s quarterly revenue was down 1.9% compared to the same quarter last year. During the same quarter last year, the firm earned ($3.42) EPS. As a group, sell-side analysts expect that Sarepta Therapeutics will post 3.95 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of SRPT. Kestra Advisory Services LLC acquired a new position in shares of Sarepta Therapeutics in the fourth quarter valued at approximately $25,000. iSAM Funds UK Ltd bought a new stake in shares of Sarepta Therapeutics during the third quarter worth $25,000. Ancora Advisors LLC raised its holdings in shares of Sarepta Therapeutics by 200.0% during the third quarter. Ancora Advisors LLC now owns 1,500 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 1,000 shares during the period. Allworth Financial LP raised its holdings in shares of Sarepta Therapeutics by 2,098.8% during the third quarter. Allworth Financial LP now owns 1,803 shares of the biotechnology company’s stock worth $35,000 after acquiring an additional 1,721 shares during the period. Finally, Parallel Advisors LLC lifted its position in Sarepta Therapeutics by 165.3% in the 3rd quarter. Parallel Advisors LLC now owns 2,016 shares of the biotechnology company’s stock valued at $39,000 after acquiring an additional 1,256 shares in the last quarter. Institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.